Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma

Two-thirds of nasopharyngeal carcinoma (NPC) patients who present with stage III-IVA-B are potentially eligible for curative chemoradiotherapy. In the 2DRT era, concurrent chemoradiotherapy (CCRT) was the standard treatment in locoregionally advanced NPC since the publication of the landmark Intergroup 0099 study [1]. Several subsequential clinical trials also confirmed the effectiveness of this treatment modality [2–4]. The current NCCN guidelines recommend that CCRT followed by adjuvant chemotherapy (AC) for locoregionally advanced NPC, originate from the results of these studies.

http://ift.tt/2wwmku8